Intravenous infusion after reolysis and dilution, 4mg/kg, single dose.

2 trials

Sponsors

Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Drug Clinical Trial Center of Xiangya Third Hospital of Central South University

Conditions

Breast cancerbreast cancer

Phase 1

Comparative pharmacokinetics of recombinant anti-HER2 humanized monoclonal antibody for injection in a single dose in healthy volunteers

Active, not recruitingChiCTR2000041577

Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South Universitybreast cancer

Start: 2014-03-06Updated: 2021-03-15

Single dose tolerance and pharmacokinetics of recombinant anti HER2 humanized monoclonal antibody for injection in healthy volunteers

Active, not recruitingChiCTR2100041802

Drug Clinical Trial Center of Xiangya Third Hospital of Central South UniversityBreast cancer

Start: 2013-09-03Updated: 2021-03-30

Related Papers

A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.

2022-02-21